Polar Capital’s Viking Therapeutics VKTX Stock Holding History

Polar Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-750,000	Closed	-$3.28M	–	269
2018 Q1	$3.28M	Buy	+750,000	New	+$4.15M	0.03%	230

Other funds holding VKTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Polar Capital's VKTX Position: Q2 2018 in Review

Polar Capital sold out of Viking Therapeutics (VKTX) in Q2 2018, closing a stake of 750,000 shares — an estimated $3.28M sold.

Polar Capital first reported a position in VKTX in Q1 2018 and held it in 1 quarter. The position peaked at $3.28M in Q1 2018. 116 funds tracked by Wall St. Rank hold VKTX as of Q2 2018.

Polar Capital reported no remaining Viking Therapeutics position as of Q2 2018 after selling out during the quarter.
Polar Capital sold 750,000 Viking Therapeutics shares in Q2 2018, an estimated $3.28M.
Polar Capital first reported a position in Viking Therapeutics in Q1 2018 and held it in 1 quarter.
Polar Capital's Viking Therapeutics position peaked at $3.28M in Q1 2018.
116 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2018.

Based on Polar Capital's 13F filing for Q2 2018, filed 14 Aug 2018.